Search Result
Results for "
nicotinamide-adenine
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0445A
-
β-DPN sodium; β-NAD sodium; β-nicotinamide adenine Dinucleotide sodium
|
Endogenous Metabolite
|
Metabolic Disease
|
NAD (β-Nicotinamide Adenine Dinucleotide) sodium is an analogue of NAD. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions which oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria that indirectly generates ATP .
|
-
-
- HY-113432
-
2PY
|
Endogenous Metabolite
PARP
|
Metabolic Disease
|
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
|
-
-
- HY-113432S
-
|
Endogenous Metabolite
PARP
|
Metabolic Disease
|
Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].
|
-
-
- HY-113325A
-
|
Endogenous Metabolite
|
Others
|
NADP sodium hydrate, a β-Nicotinamide adenine dinucleotide phosphate sodium salt, is a redox cofactor. NADP sodium hydrate is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH) .
|
-
-
- HY-W250154
-
|
Endogenous Metabolite
|
Metabolic Disease
|
β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle .
|
-
-
- HY-P2804
-
GADPH; G3PDH; Glyceraldehyde phosphate dehydrogenase
|
Others
|
Others
|
Glyceraldehyde phosphate dehydrogenase (EC 1.2.1.12) is the target of anti-thymocyte and anti-apoptotic agents. Glyceraldehyde phosphate dehydrogenase catalyzes the chain oxidation of reduced nicotinamide adenine dinucleotide by perhydroxyl radicals .
|
-
-
- HY-157421
-
|
NAMPT
|
Others
|
Nampt activator-4 is a positive allosteric modulator (N-PAM) of nicotinamide phosphoribosyltransferase (NAMPT) with an EC50 of 0.058 μM. Nampt activator-4 can enhance the nicotinamide adenine dinucleotide (NAD +) in cells .
|
-
-
- HY-B0445
-
NAD+
Maximum Cited Publications
21 Publications Verification
β-DPN; β-NAD; β-nicotinamide adenine Dinucleotide
|
Endogenous Metabolite
|
Metabolic Disease
|
NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
|
-
-
- HY-113325
-
NADP
4 Publications Verification
|
Endogenous Metabolite
|
Others
|
NADP, a nicotinamide adenine dinucleotide, is a redox cofactor. NADP is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH). NADPH is the universal electron donor in cellular reductive biosyntheses and detoxification processes, and also plays a key role in oxidative defense system .
|
-
-
- HY-100973A
-
ADP ribose sodium
|
|
|
Adenosine 5′-diphosphoribose sodium (ADP ribose sodium) is a nicotinamide adenine nucleotide (NAD +) metabolite. Adenosine 5′-diphosphoribose sodium is the most potent and primary intracellular Ca 2+-permeable cation TRPM2 channel activator. Adenosine 5′-diphosphoribose sodium also can enhance autophagy .
|
-
-
- HY-156424
-
|
Others
|
Inflammation/Immunology
|
NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox−p22phox protein−protein interaction with favorable binding affinities and cellular activities .
|
-
-
- HY-F0002
-
Sodium NADP
|
Endogenous Metabolite
|
Others
|
NADP sodium salt is the sodium salt form of NADP (HY-113325). NADP, a nicotinamide adenine dinucleotide, is a redox cofactor. NADP is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH). NADPH is the universal electron donor in cellular reductive biosyntheses and detoxification processes, and also plays a key role in oxidative defense system .
|
-
-
- HY-14374
-
GPP78
1 Publications Verification
CAY10618
|
NAMPT
Autophagy
|
Inflammation/Immunology
Cancer
|
GPP78 (CAY10618) is a potent Nampt inhibitor with an IC50 of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC50 of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects .
|
-
-
- HY-F0002A
-
Disodium NADP
|
Endogenous Metabolite
|
Others
|
NADP disodium salt is the disodium salt form of NADP (HY-113325). NADP, a nicotinamide adenine dinucleotide, is a redox cofactor. NADP is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH). NADPH is the universal electron donor in cellular reductive biosyntheses and detoxification processes, and also plays a key role in oxidative defense system .
|
-
-
- HY-150508
-
|
CD38
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
|
-
-
- HY-151936
-
|
Bacterial
|
Infection
|
LmNADK1-IN-1 (compound MC1) is an inhibitor of nicotinamide adenine dinucleotide kinases (NADK1) from L. monocytogenes with a Ki value of 54 nM. LmNADK1-IN-1 can be used for the research of bacterial infection . LmNADK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-W654288
-
β-DPN-d4; β-NAD-d4; β-nicotinamide adenine Dinucleotide-d4
|
Isotope-Labeled Compounds
|
Others
|
NAD+-d4 is the deuterium-labeled NAD+ (HY-B0445). NAD+-d4 is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
|
-
-
- HY-B0445S1
-
β-DPN-13C5; β-NAD-13C5; β-nicotinamide adenine Dinucleotide-13C5
|
Endogenous Metabolite
|
Metabolic Disease
|
NAD+- 13C5-1 is the 13C labeled NAD+[1]. NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
|
-
-
- HY-B0445S
-
β-DPN-13C5 ammonium; β-NAD-13C5 ammonium; β-nicotinamide adenine Dinucleotide-13C5 ammonium
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
NAD+-13C5 (ammonium) is the 13C labled NAD+ (HY-B0445), with an ammonium .
|
-
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-B0445A
-
β-DPN sodium; β-NAD sodium; β-nicotinamide adenine Dinucleotide sodium
|
Biochemical Assay Reagents
|
NAD (β-Nicotinamide Adenine Dinucleotide) sodium is an analogue of NAD. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions which oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria that indirectly generates ATP .
|
-
- HY-W250154
-
|
Biochemical Assay Reagents
|
β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle .
|
-
- HY-W250163
-
β-DPN lithium; β-NAD lithium; β-nicotinamide adenine Dinucleotide lithium
|
Biochemical Assay Reagents
|
NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
|
-
- HY-131485
-
3-APAD
|
Biochemical Assay Reagents
|
3-Acetylpyridine adenine dinucleotide (3-APAD) is an analog of nicotinamide adenine dinucleotide (NAD). 3-Acetylpyridine adenine dinucleotide collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P4757
-
|
Peptides
|
Others
|
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
|
-
- HY-P10026
-
LY-3457263
|
Peptides
|
Metabolic Disease
|
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .
|
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-P10016
-
HS-20039; EPO-018B
|
Peptides
|
Endocrinology
|
Pegmolesatide(HS-20039; EPO-018B) a synthetic peptide-based erythropoiesis-stimulating agent, can be used for ??the study of anemia in chronic kidney disease .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-113432S
-
|
Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].
|
-
-
- HY-B0445S1
-
|
NAD+- 13C5-1 is the 13C labeled NAD+[1]. NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
|
-
-
- HY-B0445S
-
|
NAD+-13C5 (ammonium) is the 13C labled NAD+ (HY-B0445), with an ammonium .
|
-
-
- HY-W654288
-
|
NAD+-d4 is the deuterium-labeled NAD+ (HY-B0445). NAD+-d4 is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: